건강보험 약품비의 체계적 관리를 위한 로드맵 구축
A Roadmap to Contain Pharmaceutical Expenditures under the National Health Insurance System
2
조회
0
다운로드
1
인용
0
참고문헌
초록
The growth rate of pharmaceutical expenditures covered by the National Health Insurance had been rapidly growing and also its proportion among the health expenditures had been compara- tively high (29.15% in 2011). This study presented a roadmap to contain pharmaceutical expendi- tures under the National Health Insurance System composed of five agenda, which were initiated by the National Health Insurance Service (NHIS) in the perspective of insurer in 2012. Five agenda com- posed of strengthening of the negotiation power of the insurer and diversification of risk sharing arrangement, global pharmaceutical budget system, reference pricing system, pharmaceutical ten- dering system, and public fund for orphan drugs, which were selected from the discussion among the staff in the NHIS. Then expert opinion survey were conducted to investigate stakeholers’ antici- pated impact of each 5 agenda with the criteria of pharmaceutical expenditure control, sustainablity and equity, efficiency, availability, accessibility, quality and health outcomes, satisfaction of consum- er and patient, and objective of pharmaceutical company (R&D and innovation). And anticipated in- troduction time of these agenda, policy compliance of stakeholders. 19 experts from academic, gov- ernment, pharmaceutical company, doctors, pharmacist and consumer and patient group. The roadmap to control pharmaceutical expenditures composed of 5 agenda initiated by the NHIS were presented in detail as result of experts’ opinion.
Abstract
The growth rate of pharmaceutical expenditures covered by the National Health Insurance had been rapidly growing and also its proportion among the health expenditures had been compara- tively high (29.15% in 2011). This study presented a roadmap to contain pharmaceutical expendi- tures under the National Health Insurance System composed of five agenda, which were initiated by the National Health Insurance Service (NHIS) in the perspective of insurer in 2012. Five agenda com- posed of strengthening of the negotiation power of the insurer and diversification of risk sharing arrangement, global pharmaceutical budget system, reference pricing system, pharmaceutical ten- dering system, and public fund for orphan drugs, which were selected from the discussion among the staff in the NHIS. Then expert opinion survey were conducted to investigate stakeholers’ antici- pated impact of each 5 agenda with the criteria of pharmaceutical expenditure control, sustainablity and equity, efficiency, availability, accessibility, quality and health outcomes, satisfaction of consum- er and patient, and objective of pharmaceutical company (R&D and innovation). And anticipated in- troduction time of these agenda, policy compliance of stakeholders. 19 experts from academic, gov- ernment, pharmaceutical company, doctors, pharmacist and consumer and patient group. The roadmap to control pharmaceutical expenditures composed of 5 agenda initiated by the NHIS were presented in detail as result of experts’ opinion.
참고문헌 (24)
- "OECD Health Data 2014"[URL]
- Practical health welfare plan II, National Health Insurance Service Reform Committee Activity Report, "National Health Insurance Reform Committee", National Health Insurance Service, ~ (2013)
- Drug price negotiation status and system improvement briefing session, "National Health Insurance Service", National Health Insurance Service, ~ (2008)
- Audit Result Report - Health Insurance Drug Administration, "Board of Audit and Inspection", Board of Audit and Inspection, ~ (2012)
- Population based analysis of trend and component of pharmaceutical expenditure, "Byeon JO", National Health Insurance Service, ~ (2015)
- Practical health welfare plan, National Health Insurance Service Reform Committee Activity Report, "National Health Insurance Reform Committee", National Health Insurance Service, ~ (2012)
- Future directions for pharmaceutical policy in the new era of high cost medicines, "Park S", Korea Institute for Health and Social Affairs, ~ (2011)
- Analysis of drug prescription behavior according to the policy to strengthen the protection of cancer patients, "Kim KH.", Health Insurance Review & Assessment Service, ~ (2010)
- Study on differential out-of-pocket payment for pharmaceuticals, "Park CM", Health Insurance Review & Assessment Service, ~ (2012)
- Study on drug pricing process and improvement plan, "Bae EY", Health Insurance Review & Assessment Service, ~ (2007)
- Contribution analysis by drug cost component, "Bae EY.", Health Insurance Review & Assessment Service, ~ (2007)
- A new approach to drug pricing: pricing based on risk sharing agreement. 2009 Open forum of Policy Korean Association of Health Economics and Policy, "Ryu KC.", Policy Korean Association of Health Economics and Policy, ~ (2009)
- Policy research on volume control to rationalize pharmaceutical expenditures, "Lee SM", Health Insurance Review & Assessment Service, ~ (2010)
- Development of re-evaluation of drug price considering volume, "Lee YK.", Health Insurance Review & Assessment Service, ~ (2005)
- Introduction of risk sharing agreement, "Lee TJ", National Health Insurance Service·Seoul National University, ~ (2012)
- Analysis of attributing factors of national health insurance pharmaceutical expenditures, "Jang SM", Health Insurance Review & Assessment Service, ~ (2010)
- Review and implication of global budget system in major countries, "Jeong HJ", National Health Insurance Service, ~ (2011)
- "Impact of drug price reduction policy on domestic pharmaceutical industry"[URL]
- Trends and prospects of US generic drug market, "Cho DH", Korea Health Industry Development Institute, ~ (2011)
- Positive list system design plan, "Choi SE", Health Insurance Review & Assessment Service, ~ (2007)
- Vogler S, "The impact of pharmaceutical pricing and reimbursement policies on generics uptake : implementation of policy options on generics in 29 European countries–an overview", GaBI J, 1, pp.44~51 (2012)
- Schäfer W, "The Netherlands: health system review", Health Syst Transit, 12, pp.1~228 (2010)
- Dylst P, "Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe?", Health Policy, 101, pp.146~152 (2011)
- Roadmap for comprehensive management of health insurance pharmaceutical expenditures, "Kim SO", National Health Insurance Service, ~ (2011)